drugset / Trial / NCT02751632

The Staged Treatment in Early Psychosis Study

NCT02751632

RandomizedParallel-groupTriple-blindTreatment

Summary

A sequential multistage randomised clinical trial (SMART) to produce evidence to guide a step-wise clinical approach for the treatment of ultra high risk patients and reduction of risk for psychosis and other deleterious clinical and/or functional outcomes.

Timeline

Start
2016-04
Primary completion
2019-07
Completion
2022-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluoxetine Small molecule 20 mg
Subject Fluoxetine Small molecule 40 mg